Moderna
Search results
BioNTech. We are a global immunotherapy powerhouse aspiring to translate science into survival. Read more. Interest Selector. Our mission. We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies. We believe in scientific rigor, innovation and passion as driving force.
- Our Senior Team
Prof. Pedro L. Alonso, M.D., Ph.D., joined BioNTech in 2023...
- Open Positions
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Vision & Mission
BioNTech’s portfolio contains more than 25 product...
- Newsroom
First BioNTainer arrives in Rwanda - Sierk Poetting and...
- Therapeutic Areas
BioNTech initiated a clinical phase 1 trial for an...
- Connect
You are also welcome to report to BioNTech directly or to...
- History
The Pfizer-BioNTech COVID-19 vaccine is the first vaccine to...
- Pipeline
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Collaborators
Autolus Therapeutics. In February 2024, we entered into a...
- Our Senior Team
BioNTech SE (/ b iː ˈ ɒ n t ɛ k / bee-ON-tek; or / b aɪ ˈ ɒ n t ɛ k / bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
- 2008; 15 years ago
- Mainz, Germany
- 4,530 (2022)
- Biotechnology
A transatlantic leader in individualized neoantigen-targeted T cell therapies. Based in Cambridge, MA, BioNTech US serves as BioNTech’s North American headquarters and is an important part of our global effort to pioneer the development of next-generation immuno-oncology therapies.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
- Comirnaty
- mRNA
Aug 23, 2021 · FDA approved the first COVID-19 vaccine, which has been known as the Pfizer-BioNTech COVID-19 Vaccine, and is now marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19...
Dec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted FDA approval. Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose. More than 1.2 billion Pfizer-BioNTech doses have been delivered to more than 120 countries or territories around the world since December 2020.
Oct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study ( NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of ...
